Abstract
Mesonephric adenocarcinoma is a rare tumor, accounting for <1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / genetics
-
Adenocarcinoma / pathology
-
Adult
-
Cervix Uteri / pathology
-
Diagnosis, Differential
-
Female
-
Humans
-
Mesonephroma / diagnosis*
-
Mesonephroma / genetics
-
Mesonephroma / pathology
-
Mutation
-
Receptor, Fibroblast Growth Factor, Type 2 / genetics*
-
Uterine Cervical Neoplasms / diagnosis*
-
Uterine Cervical Neoplasms / genetics
-
Uterine Cervical Neoplasms / pathology
Substances
-
FGFR2 protein, human
-
Receptor, Fibroblast Growth Factor, Type 2